Phase 2 Study of Ipilimumab in Children and Adolescents (12 to less than 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Latest Information Update: 23 Dec 2021
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 14 Jun 2019 This trial has been completed in UK (global end date: 07-07-2016).
- 26 Oct 2017 Results published in the European Journal of Cancer